GLP-1 Provider Safety Records Compared: FDA Warnings, Pharmacy Credentials, and Oversight

When you're choosing a GLP-1 telehealth provider, you're trusting them with your health — specifically, with prescribing a medication that affects your endocrine system, gastrointestinal function, and potentially your cardiovascular health. The provider's safety track record should be a non-negotiable part of your evaluation, not an afterthought.

We track three dimensions of provider safety: regulatory history (FDA warnings, state actions, legal issues), pharmacy credential verification (are their compounding partners operating legally and inspected?), and safety protocol rigor (what systems do they have in place to prevent and respond to adverse events?).

Regulatory History: What the Public Record Shows

The MEDVi FDA Warning Letter

In February 2026, MEDVi received an FDA warning letter citing concerns about manufacturing practices. This is a significant regulatory action — warning letters are public documents that indicate the FDA found violations during inspection or investigation. MEDVi has stated they are addressing the FDA's concerns, but the warning letter remains on the public record.

We are not recommending that current MEDVi patients immediately discontinue treatment — medication interruptions carry their own risks. But prospective patients should review the FDA's letter (available on the FDA website) and factor it into their provider evaluation.

Clean Regulatory Records

Most established GLP-1 telehealth providers have clean regulatory histories with no FDA warning letters, state medical board actions, or significant legal issues. This is the baseline expectation, not a differentiator — but it's worth confirming before enrolling. You can verify a provider's standing through:

• The FDA's Warning Letters database (searchable online)
• State medical board license verification (for the prescribing provider)
• State Board of Pharmacy records (for the compounding pharmacy)
• Better Business Bureau complaints and ratings

Pharmacy Credential Verification

The safety of compounded GLP-1 medications depends heavily on the compounding pharmacy's practices. Key credentials to look for:

State pharmacy board licensing. Every legitimate compounding pharmacy must be licensed in the states where it operates and ships medication. This is non-negotiable — operating without proper licensure is illegal.

503A vs 503B designation. 503B outsourcing facilities are subject to FDA inspection and must follow current Good Manufacturing Practice (cGMP) guidelines. 503A pharmacies are state-regulated and compound on an individual-patient basis. Both are legitimate, but 503B facilities generally have more rigorous quality controls.

Accreditation. Voluntary accreditation bodies like PCAB (Pharmacy Compounding Accreditation Board) provide additional quality assurance beyond minimum regulatory requirements. Providers that use PCAB-accredited pharmacies are signaling a commitment to quality that exceeds the legal minimum.

Providers With Strong Safety Profiles

Embody

Clean regulatory record, established pharmacy partnerships, and a provider-led model that includes clinical safety screening. The dedicated provider relationship means adverse events are flagged to someone who knows your treatment history.

Sesame Care

Sesame's brand-name medication model bypasses compounding entirely, eliminating the pharmacy credential question. FDA-approved medications manufactured by Novo Nordisk and Eli Lilly carry the most extensively documented safety profiles in the GLP-1 market.

Ivim Health

Ivim's insurance concierge model routes patients to brand-name medications when coverage is available, and their compounding partnerships serve patients without coverage. This dual pathway provides access to both the most-documented safety profiles (brand-name) and affordable alternatives (compounded).

GobyMeds

GobyMeds maintains a clean regulatory record at the budget price tier. At $99/month, they demonstrate that affordable pricing doesn't require cutting corners on pharmacy quality or regulatory compliance.

Safety Red Flags to Watch For

When evaluating any GLP-1 provider's safety practices, watch for:

• Refusal to name their compounding pharmacy. You have a right to know who manufactured your medication. Providers that won't share this information may be hiding quality concerns.
• No adverse event reporting process. Legitimate providers should have a clear system for patients to report side effects and adverse events — and a protocol for responding to them.
• No mention of contraindications. GLP-1 medications have specific contraindications (thyroid cancer history, pancreatitis, pregnancy). If the enrollment process doesn't screen for these, the provider is skipping fundamental safety checks.
• International sourcing without disclosure. If your medication is compounded overseas, you should know. International compounding pharmacies may not be subject to US regulatory oversight, and the legality of importing compounded medications varies.
• Price points that seem unsustainably low. Legitimate compounded semaglutide has a floor cost for raw ingredients, compounding labor, cold-chain shipping, and clinical oversight. If a provider offers pricing dramatically below the market (say, $40/month), the economics may require shortcuts somewhere in the supply chain.

Provider Safety Comparison